Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBITDA Margin: 2021-2025

Historic EBITDA Margin for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to -3.44%.

  • Immunocore Holdings' EBITDA Margin fell 1837.00% to -3.44% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.39%, marking a year-over-year increase of 30.00%. This contributed to the annual value of -15.66% for FY2024, which is 88.00% down from last year.
  • Per Immunocore Holdings' latest filing, its EBITDA Margin stood at -3.44% for Q3 2025, which was up 11.82% from -3.90% recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' EBITDA Margin ranged from a high of 14.93% in Q3 2024 and a low of -33.39% during Q1 2024.
  • Moreover, its 3-year median value for EBITDA Margin was -14.15% (2024), whereas its average is -11.53%.
  • Per our database at Business Quant, Immunocore Holdings' EBITDA Margin crashed by 3,055bps in 2024 and then surged by 3,945bps in 2025.
  • Over the past 4 years, Immunocore Holdings' EBITDA Margin (Quarterly) stood at 0.20% in 2021, then reached -0.82% in 2023, then tumbled by 3,055bps to -31.36% in 2024, then crashed by 1,837bps to -3.44% in 2025.
  • Its EBITDA Margin was -3.44% in Q3 2025, compared to -3.90% in Q2 2025 and 6.07% in Q1 2025.